Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Reduces Position in Moderna, Inc. (NASDAQ:MRNA)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 19.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 490 shares of the company’s stock after selling 120 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Moderna were worth $50,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. IFP Advisors Inc increased its position in Moderna by 18.8% during the third quarter. IFP Advisors Inc now owns 834 shares of the company’s stock valued at $86,000 after acquiring an additional 132 shares during the last quarter. Ritholtz Wealth Management boosted its holdings in shares of Moderna by 27.1% in the third quarter. Ritholtz Wealth Management now owns 2,122 shares of the company’s stock worth $219,000 after buying an additional 452 shares during the last quarter. HB Wealth Management LLC grew its position in Moderna by 49.2% during the third quarter. HB Wealth Management LLC now owns 3,192 shares of the company’s stock valued at $330,000 after buying an additional 1,052 shares during the period. Flagship Harbor Advisors LLC increased its holdings in Moderna by 13.1% during the third quarter. Flagship Harbor Advisors LLC now owns 4,537 shares of the company’s stock valued at $469,000 after buying an additional 526 shares during the last quarter. Finally, Avior Wealth Management LLC boosted its stake in shares of Moderna by 219.9% during the 3rd quarter. Avior Wealth Management LLC now owns 3,097 shares of the company’s stock worth $320,000 after acquiring an additional 2,129 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

NASDAQ:MRNA opened at $107.89 on Wednesday. The company has a market cap of $41.31 billion, a price-to-earnings ratio of -8.69 and a beta of 1.62. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $142.79. The stock’s 50 day simple moving average is $101.39 and its two-hundred day simple moving average is $93.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. Moderna’s quarterly revenue was down 44.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.61 earnings per share. As a group, equities analysts anticipate that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total value of $1,550,700.00. Following the completion of the sale, the director now directly owns 2,056,931 shares of the company’s stock, valued at approximately $212,645,526.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now directly owns 8,557 shares in the company, valued at approximately $809,235.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the completion of the sale, the director now directly owns 2,056,931 shares of the company’s stock, valued at approximately $212,645,526.78. The disclosure for this sale can be found here. Over the last quarter, insiders sold 109,954 shares of company stock worth $11,533,976. Corporate insiders own 15.20% of the company’s stock.

Analyst Ratings Changes

MRNA has been the subject of several recent research reports. HSBC reissued a “reduce” rating and set a $86.00 price target (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Canaccord Genuity Group increased their target price on shares of Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a report on Friday, February 23rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Royal Bank of Canada restated an “outperform” rating and set a $125.00 price objective on shares of Moderna in a research report on Thursday, March 28th. Finally, William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $126.49.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.